[Systemic therapy of penile cancer].

Abstract

Penile cancer is a rare tumor in Europe with an incidence of 0.1-0.9 per 100,000 men per year. The success of our therapy is mainly influenced by the presence of lymph node metastases. At first diagnosis 17-45% of patients already harbor lymph node metastases. Bilateral inguinal and pelvic lymphadenectomy is a curative measure in these patients. In cases of gross inguinal metastases neoadjuvant chemotherapy leads to a remission rate of 21-60% and improves the resectability. The influence on survival is not proven. The same holds true for adjuvant therapy following lymphadenectomy. Polychemotherapy rarely leads to long-lasting complete remission in patients with distant metastases. The protocols consist usually of cisplatin, bleomycin, methotrexate, and 5-fluorouracil. The overall remission rate is around 15-32%. Because of the low efficacy of the present chemotherapy regimens, one should follow new strategies, comparable to those initiated for squamous cell cancer of other organs.

• Authors: E Preis, P Albers, G Jakse
• Journal: Der Urologe. Ausg. A (Urologe A) Vol. 45 Issue 5 Pg. 609-13 (May 2006) ISSN: 0340-2592 [Print] Germany
• Vernacular Title: Die systemische Therapie des Peniskarzinoms.
• PMID: 16622642 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant (methods)
• Clinical Trials as Topic
• Humans
• Male
• Neoadjuvant Therapy (methods)
• Penile Neoplasms (drug therapy, mortality)
• Practice Guidelines as Topic
• Practice Patterns, Physicians'
• Terminal Care (methods)